SCHEMBL24343

SCHEMBL24343

[c]1ccc2ccc3ncccc3c2n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
MAPT P10636 3/20 0.50
KDM4E B2RXH2 2/20 0.50
CYP3A4 P08684 2/20 0.50
HTT P42858 3/20 0.41
HSP90AA1 P07900 2/20 0.41
HIF1A Q16665 2/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
MMP2 P08253 1/20 0.41
CYP2D6 P10635 1/20 0.41
MMP9 P14780 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24930 0.79 LMNA (0.62) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL67041 0.78 CCR1 (0.64) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL2016968 0.78 MAPT (0.64) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL8313 0.77 LMNA (1.00) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL6513577 0.77 LMNA (1.00) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL2519517 0.77 KDM4E (0.50) LMNAKDM4EERN1CYP1A2
Pyrazine SCHEMBL28719971 0.77 LMNA (0.89) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL7142651 0.76 LMNA (0.96) LMNAMAPTKDM4ECYP3A4HTT
Iodide SCHEMBL10638043 0.76 LMNA (0.96) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL15788918 0.76 LMNA (0.96) LMNAMAPTKDM4ECYP3A4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49118-E1 Material for organic electroluminescence device and electroluminescence device employing the same IDEMITSU KOSAN CO., LTD. (JP) 2022-06-28 US claimed
CN-112390811-B Dithia-anthrone derivative and preparation method and application thereof 中国科学院理化技术研究所 2022-03-04 CN claimed
CN-114057711-A Anthracene ketone spiro derivative and preparation method and application thereof 中国科学院理化技术研究所 2022-02-18 CN claimed
CN-107556298-B Aromatic heterocyclic derivative, material for organic electroluminescent element, and organic electroluminescent element 出光兴产株式会社 2021-12-21 CN claimed
CN-107586290-B Aromatic heterocyclic derivative, material for organic electroluminescent element, and organic electroluminescent element 出光兴产株式会社 2021-05-11 CN claimed
CN-112390811-A Dithia-anthrone derivative and preparation method and application thereof 中国科学院理化技术研究所 2021-02-23 CN claimed
US-10550203-B2 Polymers functionalized with heterocyclic nitrile compounds BRIDGESTONE CORPORATION (JP) 2020-02-04 US claimed
CN-110551054-A maleimide derivative, and preparation method and application thereof TECHNICAL INST PHYSICS & CHEMISTRY CAS 2019-12-10 CN claimed
US-10283717-B2 Organic electroluminescent device using aryl amine derivative containing heterocycle IDEMITSU KOSAN CO., LTD. (JP) 2019-05-07 US claimed
US-20180319905-A1 POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS BRIDGESTONE CORPORATION (JP) 2018-11-08 US claimed
EP-1913011-A2 OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE Alnylam Pharmaceuticals Inc. (US) 2008-04-23 EP claimed
US-20080076903-A1 DATA STORAGE MEDIUM AND METHOD FOR HIGH DENSITY DATA STORAGE INTERNATIONAL BUSINESS MACHINES CORPORATION 2008-03-27 US claimed
EP-1789553-A2 OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE Alnylam Pharmaceuticals Inc. (US) 2007-05-30 EP claimed
EP-1768998-A2 SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY Alnylam Pharmaceuticals Inc. (US) 2007-04-04 EP claimed
EP-1750776-A2 OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE Alnylam Pharmaceuticals Inc. (US) 2007-02-14 EP claimed
WO-2006112872-A2 OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE ALNYLAM PHARMACEUTICALS, INC. (US) 2006-10-26 WO claimed
WO-2006088490-A2 OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE ALNYLAM PHARMACEUTICALS, INC. (US) 2006-08-24 WO claimed
WO-2006078278-A2 SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY ALNYLAM PHARMACEUTICALS, INC. (US) 2006-07-27 WO claimed
WO-2006073458-A2 OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE ALNYLAM PHARMACEUTICALS, INC. (US) 2006-07-13 WO claimed
US-20050288244-A1 Oligonucleotides comprising a C5-modified pyrimidine ALNYLAM PHARMACEUTICALS, INC. (US) 2005-12-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10283717-B2 Organic electroluminescent device using aryl amine derivative containing heterocycle SLC18A1, SLC18A2, AOC2 LMNA 3089/4885MAPT 2683/4885KDM4E 2498/4885
US-20050288244-A1 Oligonucleotides comprising a C5-modified pyrimidine DUT, TYMP, DPYD LMNA 4061/4885MAPT 4345/4885KDM4E 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.